Good News for CLN1 Disease and a Sprint to the Finish
Last week, Taysha Gene Therapies announced the company has entered into license and inventory purchase agreements with Abeona Therapeutics for ABO-202, an adeno-associated virus (AAV) gene therapy for CLN1 disease (Batten disease). In the longest race, this news is a huge leap forward for children…